Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactococcus lactis JCM 5805
- Development stage
- Unknown
- Lead developer
- Kyowa Kirin
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactococcus lactis JCM 5805 is a specific, heat-killed lactic acid bacterium developed as a probiotic immunomodulator. Its primary mechanism is the selective activation of plasmacytoid dendritic cells (pDCs), which results in upregulation of type I and III interferon production and enhancement of antiviral immune responses, mediated via a TLR9-dependent pathway. It has been studied as an oral supplement for prevention of viral infections (including influenza and COVID-19), reduction of infections and immune fatigue in athletes, and, more broadly, as an immune health ingredient. Efficacy data shows its oral administration stimulates enteric immune signaling with systemic effects. It is manufactured and commercialized as a functional ingredient for dietary supplements and functional foods, principally under the brand IMMUSE[1][2][4][5][7][10].
- Brand names
- IMMUSE
- Other names
- Lactococcus lactis subsp. lactis JCM 5805LC-PlasmaJCM5805JCM-5805JCM 5805Lactococcus lactis strain Plasma
02
Targets
TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on Lactococcus lactis JCM 5805.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactococcus lactis JCM 5805.